CLDX insider transaction filings
Celldex Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-29. Screen CLDX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 18 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Brownlie Keith L — Director | 1 | — | — | 1 |
| CONRAD HERBERT J — Director | 1 | — | — | 1 |
| Cavanaugh Sarah — SVP OF CORP AFFAIRS & ADMIN. | 1 | — | — | 1 |
| Cohen Cheryl — Director | 1 | — | — | 1 |
| Crowley Elizabeth — SR. VP & CPDO | 1 | — | — | 1 |
| Heath-Chiozzi Margo — SVP OF REGULATORY AFFAIRS | 1 | — | — | 1 |
| Jain Rita — Director | 1 | — | — | 1 |
| Jimenez Freddy A. — SVP & GENERAL COUNSEL | 1 | — | — | 1 |
| KELER TIBOR — EXECUTIVE VP & CSO | 1 | — | — | 1 |
| Lawver Teri L — SVP & Chief Commercial Officer | 1 | — | — | 1 |
+8 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Celldex Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Lawver Teri L — SVP & Chief Commercial Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Jimenez Freddy A. — SVP & GENERAL COUNSEL | Grant/award (A): 93,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Torres Denice — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Heath-Chiozzi Margo — SVP OF REGULATORY AFFAIRS | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Cavanaugh Sarah — SVP OF CORP AFFAIRS & ADMIN. | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Martin Samuel Bates — SVP AND CFO | Grant/award (A): 93,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Jain Rita — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Crowley Elizabeth — SR. VP & CPDO | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Young Diane C. — SVP, CHIEF MEDICAL OFFICER | Grant/award (A): 57,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | NEIL GARRY ARTHUR — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Cohen Cheryl — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Brownlie Keith L — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Marucci Anthony S — PRESIDENT & CEO, Director | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | KELER TIBOR — EXECUTIVE VP & CSO | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | CONRAD HERBERT J — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | PEPIN RONALD — SR. VP & CBO | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | MARINO JAMES J — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | PENNER HARRY JR — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Martin Samuel Bates — SVP AND CFO | Option exercise (M): 4,817 @ $10.38 · Option exercise (M): 4,817 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | PEPIN RONALD — SR. VP & CBO | Option exercise (M): 8,333 @ $9.02 · Option exercise (M): 11,000 @ $2.78 · Option exercise (M): 8,333 (derivative) @ $0 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Jimenez Freddy A. — SVP & GENERAL COUNSEL | Sale (S): 4,166 @ $29.09 | EDGAR |
| 2025-11-17 | 4 | Wright Richard M. | Option exercise (M): 6,876 @ $9.02 · Option exercise (M): 26,672 @ $10.38 · Option exercise (M): 15,750 @ $22.48 · Sale (S): 49,298 @ $24.00 · Option exercise (M): 6,876 (derivative) @ $0 · Option exercise (M): 26,672 (derivative) @ $0 · +1 more | EDGAR |
| 2025-11-12 | 4 | Lawver Teri L — SVP & Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | Jimenez Freddy A. — SVP & GENERAL COUNSEL | Sale (S): 341 @ $23.95 · Sale (S): 430 @ $25.41 | EDGAR |
| 2025-06-09 | 4 | Jimenez Freddy A. — SVP & GENERAL COUNSEL | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Torres Denice — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Heath-Chiozzi Margo — SVP OF REGULATORY AFFAIRS | Grant/award (A): 82,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Cavanaugh Sarah — SVP OF CORP AFFAIRS & ADMIN. | Grant/award (A): 78,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Martin Samuel Bates — SVP AND CFO | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Jain Rita — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Crowley Elizabeth — SR. VP & CPDO | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Young Diane C. — SVP, CHIEF MEDICAL OFFICER | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | NEIL GARRY ARTHUR — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Cohen Cheryl — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Brownlie Keith L — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Marucci Anthony S — PRESIDENT & CEO, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | KELER TIBOR — EXECUTIVE VP & CSO | Grant/award (A): 93,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | CONRAD HERBERT J — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PEPIN RONALD — SR. VP & CBO | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MARINO JAMES J — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PENNER HARRY JR — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | MARINO JAMES J — Director | Gift (G): 10,500 @ $0 | EDGAR |
| 2024-11-12 | 4 | Marucci Anthony S — PRESIDENT & CEO, Director | Purchase (P): 11,500 @ $26.82 | EDGAR |
| 2024-06-18 | 4 | Martin Samuel Bates — SVP AND CFO | Option exercise (M): 3,201 @ $9.02 · Option exercise (M): 16,968 @ $10.38 · Sale (S): 17,172 @ $35.42 · Option exercise (M): 3,201 (derivative) @ $0 · Option exercise (M): 16,968 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Crowley Elizabeth — SR. VP & CPDO | Option exercise (M): 30,000 @ $10.38 · Sale (S): 30,000 @ $34.87 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Shoos Karen L. — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | CONRAD HERBERT J — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | PEPIN RONALD — SR. VP & CBO | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | MARINO JAMES J — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | PENNER HARRY JR — Director | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Celldex Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CLDX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →